"Dasatinib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
Descriptor ID |
D000069439
|
MeSH Number(s) |
D02.886.675.184 D03.383.129.708.198 D03.383.742.148
|
Concept/Terms |
Dasatinib- Dasatinib
- N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
BMS 354825- BMS 354825
- 354825, BMS
- BMS354825
- BMS-354825
|
Below are MeSH descriptors whose meaning is more general than "Dasatinib".
Below are MeSH descriptors whose meaning is more specific than "Dasatinib".
This graph shows the total number of publications written about "Dasatinib" by people in this website by year, and whether "Dasatinib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2006 | 0 | 10 | 10 |
2007 | 0 | 15 | 15 |
2008 | 0 | 19 | 19 |
2009 | 0 | 38 | 38 |
2010 | 0 | 32 | 32 |
2011 | 0 | 19 | 19 |
2012 | 0 | 17 | 17 |
2013 | 0 | 18 | 18 |
2014 | 1 | 8 | 9 |
2015 | 11 | 6 | 17 |
2016 | 9 | 6 | 15 |
2017 | 6 | 4 | 10 |
2018 | 9 | 7 | 16 |
2019 | 5 | 3 | 8 |
2020 | 5 | 8 | 13 |
2021 | 2 | 5 | 7 |
2022 | 0 | 7 | 7 |
2023 | 0 | 8 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dasatinib" by people in Profiles.
-
Fucoidan-mediated targeted delivery of dasatinib-loaded nanoparticles amplifies apoptosis and endows cytotoxic potential in triple-negative breast cancer. Colloids Surf B Biointerfaces. 2024 Jan; 233:113631.
-
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):149-157.
-
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. J Immunother Cancer. 2023 10; 11(10).
-
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul; 10(7):e510-e520.
-
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):742-748.
-
Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023 04 24; 13(1):58.
-
Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023 06; 37(6):1194-1203.
-
Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PLoS One. 2023; 18(3):e0281063.
-
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
-
Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. JAMA Oncol. 2022 09 01; 8(9):1340-1348.